Takeda pharmaceutical signed a $300 million cancer ADC drug development agreement with mersana

Source: Biovalley 2015-01-14 Takeda pharmaceutical, a famous Japanese pharmaceutical company, recently announced that it has signed a US $300 million cooperative R & D agreement with cancer drug R & D company mersana therapeutics The agreement is based on a partnership between the two companies reached last April In this cooperation, the two sides will carry out research on antibody drug coupling technology (ADC) Antibody drug coupling technology is a kind of targeted treatment technology rising in recent years By coupling tumor drugs and specific antibodies, the drugs can be enriched to specific lesions This breakthrough can strengthen the concentration of drugs in the lesions to enhance the efficacy, on the other hand, it can protect healthy tissues from drug damage and reduce the clinical effect The pain of cancer patients However, mersana is not infamous Since its establishment, the company has focused on the research and development of antibody drugs Its fleximer technology platform can better promote the coupling of tumor drugs and antibodies Under the agreement, Takeda will pay mersana a a total of $300 million, including advance payments and milestone funds As we all know, since Takeda pharmaceutical acquired Millennium pharmaceuticals and established its own cancer drug research and development system, the company has been seeking to expand its strength in the field of cancer drug research and development This agreement provides the best opportunity for the company to achieve this goal According to Takeda, the two sides have carried out some confirmatory studies on the cooperative drugs, and may select more drug candidates for experiments On the other hand, mersana is also willing to work more closely with Takeda In fact, since 2014, the field of immunotherapy research on cancer has continued to heat up, mersana company has also become the hot spot in the eyes of major biomedical giants Mersana has established cooperative relations with Merck, endo and adimab